Skip to main content

Table 2 Baseline characteristics of MASLD patients with and without sarcopenia in the US cohort

From: Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States

Variables

Total

(n = 821)

Non-Sarcopenia

(n = 688)

Sarcopenia

(n = 133)

P

Gender, n (%)

   

0.200

 Male

415 (50.55)

341 (49.56)

74 (55.64)

 

 Female

406 (49.45)

347 (50.44)

59 (44.36)

 

Age (years)

43.00 (32.00, 52.00)

42.00 (31.00, 51.00)

48.00 (32.00, 54.00)

0.002

BMI (kg/m2)

31.70 (27.80, 36.50)

31.20 (27.70, 35.50)

36.00 (29.80, 41.20)

< 0.001

WC (cm)

104.20 (95.40, 116.10)

103.00 (94.60, 113.73)

113.30 (100.60, 123.50)

< 0.001

FPG (mg/dL)

95.00 (88.00, 106.00)

94.00 (88.00, 104.00)

97.00 (91.00, 115.00)

< 0.001

HbA1c (%)

5.60 (5.30, 6.10)

5.60 (5.30, 6.00)

5.80 (5.40, 6.20)

0.006

TC (mg/dL)

193.00 (168.00, 217.00)

194.00 (167.75, 217.25)

190.00 (176.00, 215.00)

0.752

TG (mg/dL)

145.00 (100.00, 215.00)

144.00 (97.00, 214.00)

152.00 (121.00, 223.00)

0.039

HDL-c (mg/dL)

45.00 (39.00, 53.00)

45.00 (39.00, 54.00)

42.00 (38.00, 50.00)

0.015

AST (U/L)

20.00 (16.00, 25.00)

20.00 (16.00, 25.00)

20.00 (16.00, 24.00)

0.723

ALT (U/L)

23.00 (16.00, 33.00)

23.00 (16.00, 33.00)

24.00 (16.00, 34.00)

0.319

GGT (IU/L)

26.00 (18.00, 41.00)

25.00 (17.00, 39.00)

29.00 (20.00, 50.00)

0.005

Total Bilirubin (mg/dL)

0.40 (0.30, 0.50)

0.40 (0.30, 0.50)

0.40 (0.30, 0.50)

0.433

Creatinine (mg/dL)

0.80 (0.67, 0.95)

0.82 (0.68, 0.96)

0.73 (0.62, 0.88)

< 0.001

Uric acid (mg/dL)

5.60 (4.60, 6.50)

5.60 (4.60, 6.50)

5.50 (4.70, 6.80)

0.533

BUN (mg/dL)

13.00 (11.00, 16.00)

13.00 (11.00, 16.00)

13.00 (11.00, 15.00)

0.297

C-Reactive Protein (mg/L)

2.72 (1.24, 5.51)

2.57 (1.21, 5.31)

3.28 (1.48, 6.66)

0.015

Smoke, n (%)

   

0.777

 Yes

263 (32.03)

219 (31.83)

44 (33.08)

 

 No

558 (67.97)

469 (68.17)

89 (66.92)

 

Alcohol, n (%)

   

0.013

 Yes

345 (42.02)

302 (43.90)

43 (32.33)

 

 No

476 (57.98)

386 (56.10)

90 (67.67)

 

Physical Activity, n (%)

   

0.054

 Inactive

169 (20.58)

135 (19.62)

34 (25.56)

 

 Moderate

260 (31.67)

212 (30.81)

48 (36.09)

 

 Vigorous

392 (47.75)

341 (49.56)

51 (38.35)

 

Diabetes mellitus, n (%)

   

0.009

 Yes

166 (20.22)

128 (18.60)

38 (28.57)

 

 No

655 (79.78)

560 (81.40)

95 (71.43)

 

Hypertension, n (%)

   

0.998

 Yes

253 (30.82)

212 (30.81)

41 (30.83)

 

 No

568 (69.18)

476 (69.19)

92 (69.17)

 

LSM (kpa)

5.40 (4.40, 6.60)

5.30 (4.30, 6.50)

6.00 (4.80, 7.80)

< 0.001

CAP (dB/m)

309.00 (288.00, 341.00)

308.00 (287.00, 339.00)

316.00 (293.00, 349.00)

0.005

ASMI

0.73 (0.60, 0.90)

0.79 (0.61, 0.92)

0.68 (0.49, 0.75)

< 0.001

Significant fibrosis, n (%)

   

< 0.001

 Yes

131 (15.96)

96 (13.95)

35 (26.32)

 

 No

690 (84.04)

592 (86.05)

98 (73.68)

 

Advanced fibrosis, n (%)

   

< 0.001

 Yes

59 (7.19)

38 (5.52)

21 (15.79)

 

 No

762 (92.81)

650 (94.48)

112 (84.21)

 

Cirrhosis, n (%)

   

0.013

 Yes

31 (3.78)

21 (3.05)

10 (7.52)

 

 No

790 (96.22)

667 (96.95)

123 (92.48)

 
  1. Data are shown as median (25th, 75th percentiles) or percentages, p < 0.05 considered statistically significant
  2. Abbreviations: MASLD Metabolic dysfunction-associated steatotic liver disease, BMI Body mass index, WC Waist circumference, FPG Fasting plasma-glucose, HbA1c Hemoglobin A1c, TC Total cholesterol, TG Triglyceride, HDL-c High-density lipoprotein cholesterol, AST Aspartate aminotransferase, ALT Alanine transaminase, GGT Gamma-glutamyl transferase, BUN Blood urea nitrogen, LSM Liver stiffness measurement, CAP Controlled attenuation parameter, ASMI Appendicular skeletal muscle mass index
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us